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Abstract
Background: The population dynamics of the various clones of cancer cells existing
within a tumour is complex and still poorly understood. Cancer cell clones can be
conceptualized as sympatric asexual species, and as such, the application of
theoretical population genetics as it pertains to asexual species may provide
additional insights.
Results: The number of generations of tumour cells within a cancer has been
estimated at a minimum of 40, but high cancer cell mortality rates suggest that the
number of cell generations may actually be in the hundreds. Such a large number of
generations would easily allow natural selection to drive clonal evolution assuming
that selective advantages of individual clones are within the range reported for free-
living animal species. Tumour cell clonal evolution could also be driven by variation
in the intrinsic rates of increase of different clones or by genetic drift. In every
scenario examined, the presence of cancer stem cells would require lower selection
pressure or less variation in intrinsic rates of increase.
Conclusions: The presence of cancer stem cells may result in more rapid clonal
evolution. Specific predictions from theoretical population genetics may lead to a
greater understanding of this process.
Background
Cancers have been referred to as microcosms of evolution [1,2]; different genetic
clones within a given cancer mutate, compete and evolve resulting in the final outcome
of a malignant neoplasm. A number of excellent recent reviews of this process have
been published [1-4]. Because cancer cell clones can be thought of essentially as sym-
patric asexual species [3,5], theoretical population genetics as it applies to asexually
reproducing organisms may provide additional valuable insights into the dynamics of
cancer clonal evolution. With a few notable exceptions, however [5-9], largely missing
from this discussion has been the inclusion of predictions from theoretical population
genetics as they pertain to the population dynamics of asexually reproducing species.
Such an approach is both timely and necessary as much remains to be elucidated
about the population dynamics and evolutionary parameters of cancer cells [1].
The potential presence of cancer stem cells adds a further dimension to tumour clo-
nal evolution. Cancer stem cells (a subpopulation of tumour cells with limitless replica-
tion ability and variable treatment resistance [10-17] have been described for a number
of cancers, although the importance of cancer stem cells is still a matter of
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clonal evolution [12], but there is no reason that cancer stem cells may not themselves
undergo clonal evolution [18].
In this paper I present several concepts from population genetics which have rele-
vance to the population biology of tumour clones. I have not attempted to show the
derivation of the equations presented here - interested readers should consult estab-
lished reference sources if they require further information [19-22]. The specific issues
I will to address are (1) how quickly can mutations favourable to the growth of a can-
cer accumulate in a given clone? (2) what are the mechanisms by which one cancer
clone can replace another? and (3) how might these factors be affected by the presence
of cancer stem cells?
Results
Accumulation of mutations favourable to the growth of a cancer
What mutations are “favourable” to a cancer cell?
Favourable mutations to a cancer cell could include mutations which enhance the
growth potential of a cancer cell clone, aid in overcoming an anti-cancer defence
mechanism, or aid in the competitive advantage of a given cell clone. Mutations
favourable to the growth of a cancer cell may of course be detrimental to the ultimate
survival of the host. As Merlo et al. [1] argued, “I tm i g h tb et h a tm o s tg e n e si nt h e
human genome are devoted to building and maintaining a multicellular body, and are
therefore irrelevant to a neoplastic cell under selection for increased survival and pro-
liferation”. In fact the shedding of “unnecessary” metabolic processes may even provide
a further reproductive advantage for a cancer cell as it may reduce the diversion of
energy away from cell division.
Although an individual cancer may have 11,000 different mutations [23], or perhaps
orders of magnitude more [24], the number of significant genetic changes in carcino-
mas required to produce a malignant phenotype is estimated to be in the range of 3-7
[4,23,25,26]. So with respect to “favourable mutations”, I am referring to this subset of
genetically important mutations and not to the large number of background mutations.
Muller’s ratchet
In sexually reproducing organisms like Humans, meiosis and natural selection work in
tandem to remove deleterious mutations from the gene pool in the following way:
meiosis randomly assorts the mutations among offspring and natural selection then
removes the deleterious mutations through differential survival of those offspring.
However as Muller pointed out nearly 80 years ago [27], asexually reproducing organ-
isms lack a mechanism to remove deleterious mutations from the population. The cor-
ollary is that in asexual species there is also no mechanism to quickly combine
favourable mutations in a single clone. For example, if three favourable mutations (A,
B and C) all arose in a given sexually reproducing population, genetic recombination
could assort these mutations into a single organism in a limited number of genera-
tions. However, in an asexually reproducing population, the only way for a single clo-
nal line to possess all three mutations is if an individual already possessing one of the
mutations (say, mutation A) then acquires mutation B, and finally a descendent of this
clone then acquires mutation C. A general estimate of the number of generations
necessary between the establishment of one favourable mutation and the establishment
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log (N/s) [19], where G = the number of generations, N = population size, and s =t h e
selective advantage of the new mutation. I will come back to selective advantage later.
Of course, while it is true that mutations may be numerically more likely to arise in
larger populations, the counterintuitive prediction is that such mutations may arise
and become established more quickly in smaller populations. Table 1 shows that if we
apply this equation to a series of hypothetical cancers of different sizes, we get the pre-
diction that new favourable mutations will become established in a given cancer clone
faster when the tumour is smaller. Likewise, for cancer stem cells, favourable muta-
tions are predicted to become established at a faster rate in a stem cell model for any
size of tumour but are predicted to be established most quickly in smaller cancers
(Table 1)[28]. Several previous studies have reported an association between tumour
heterogeneity and malignant potential [29,30]. The prediction of faster clonal evolution
in smaller tumours could also mean that in the fragmented (i.e. smaller) subpopula-
tions associated with genetic heterogeneity, new mutations may become established at
a faster rate, thus adding to the malignant potential of genetically heterogeneic
tumours.
Finally, if we consider a cancer stem cell model where clonal evolution is occurring
o n l yi nas u b s e to ft h ec a n c e rc e l l s( t h es t e mc e l l s )w ec a ns e et h a tf o ra n ys i z eo f
tumour, because of the much smaller number of stem cells, clonal evolution is pre-
dicted to be faster in stem cells compared to non-stem cells.
What are the mechanisms by which one cancer cell clone can replace another?
The previous section dealt with the question of how quickly new favourable mutations
may arise and become established. However, especially in large tumours, the time
required for a new favourable mutation too c c u p yal a r g ep a r to ft h et u m o u rm a s si s
also important [6]. So I will now turn to the question of how one clone can come to
Table 1 Number of generations for a favourable mutation to become established in a
tumour cell clone [20]
Tumour Size
(cm)
Number of
cells
Estimated number of
generations
to establish a favourable
mutation in a somatic
cell clone
Estimated number of
generations
to establish a favourable
mutation
in a stem cell clone
0.1 4 189 6 1
0.5 523 599 8 3
1.0 4 188 790 9 4
2.0 33 510 322 10 5
3.0 11 3097 336 10 5
4.0 268 082 573 10 6
5.0 523 598 776 11 6
10.0 4 188 790 205 12 7
The results are rounded to the nearest whole number. The results were calculated by assuming a fairly weak selective
advantage of 0.01 for the new clone. The number of cells as calculated by determining the number of cubes, 50
micrometers on a side, which would fill a sphere representing a tumour of a given size. The number of stem cells is
calculated by assuming one stem cell per 57 000 non-stem cells [28]. A greater proportion of stem cells would result in
a less dramatic difference.
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occur: genetic drift, variation in the growth rate (intrinsic rate of increase) of different
clones and selection pressure favouring one clone over another.
Genetic drift
Recall that Muller’s ratchet describes the situation where deleterious mutations may
accumulate in an asexual population because of genetic drift as there is no mechanism
to remove them. Conversely, favourable mutations could conceivably be aided in their
increase by genetic drift but this effect may be difficult to disentangle from the other
mechanisms outlined below. Accumulation of mutations by drift therefore is more
relevant to mutations that are selectively neutral or deleterious to the cancer cell
clone. For mutations that are deleterious, random drift will tend to fix a mutation if
U/s > 1 [19] where U = the total number of mutations per genome and s = the selec-
tion pressure against individual mutations. Stoler et al. [23] estimated that there are at
least 11,000 genomic alterations in the clone that generates a colon carcinoma. Other
comparative work has suggested that approximately 25% of amino acid replacements
destroy the resulting protein function [31], indicating that many of the mutations
observed in cancer cells may be deleterious. The presence of such a large number of
mutations (or even more by another estimate [32]) suggests that many mutations, even
ones which are deleterious to the cancer clone, will accumulate and increase to fixation
by random drift alone. Furthermore, as the number of mutations is likely much higher
than the selection pressure against any given mutation, we would expect that even
some mutations which are highly selected against will increase in the tumour. Finally
as the number of mutations in a given cancer increase in the later stages of clonal evo-
lution, we could also make the prediction that genetic drift may be more important in
the later stages of a tumour, because of the increased number of mutations, despite
the fact that the absolute number of cancer cells is also larger.
Variation in the intrinsic rate of increase
The rate at which a population increases is known as its intrinsic rate of increase and
is described by the equation dx/dt = rx [20] where dx is the change in the number of
individuals over time, dt is the time interval, r is the intrinsic rate of increase and x is
the starting population size. Another way to think of r is as the ‘compound interest’ on
the increase in population size. Consider the situation where two cancer clones exist
within a tumour. They do not directly compete with each other (i.e. there is no selec-
tion) but they do differ in the speed with which they divide (their intrinsic rate of
increase). In this situation, the clone with the higher intrinsic rate of increase will
eventually overtake the slower growing clone even in the absence of any selection pres-
s u r e .F o rt w oc l o n e s( A and a) with overlapping generations the rate of change
(expressed as the change in proportion of A to a is given by the equation G = [ln (Pt/
(1-Pt)-l n( P 0/(1- P0)]/(rA -r a)[ 2 2 ]w h e r eG = the number of cell generations, P0 =
the starting proportion of the two clones, Pt = the final proportion of the two clones,
rA =t h ei n t r i n s i cr a t eo fi n c r e a s eo fc l o n eA and ra = the intrinsic rate of increase of
clone a. Table 2 shows that for small differences in the intrinsic rates of increase
between the clones, the number of generations needed for one clone to replace
another are very long. However, larger differences in intrinsic rates of increase could
result in fairly rapid replacement of one clone by another. In the absence of selection,
if two clones differ little in their relative rates of increase, the selective replacement of
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additional mutations to arise, resulting in greater clonal heterogeneity.
Selection
There are several reasons to expect that competition exists among cancer clones and
may in fact be intense. First of all, the environment within a tumour is often character-
ized by high tumour cell density and areas of tumour cell necrosis suggesting that
there are limiting environmental factors to cell survival. Furthermore, hypoxia, host
immune responses and therapeutic interventions may create sequential bottlenecks at
which selection for the best adapted cancer cell clones could occur [1,3]. The existence
of periods of intense selection within a cancer is further supported by finding that
tumours may undergo periodic genetic homogenization [33].
Secondly, it is likely that the majority of cancer cells die as a tumour grows. Surgical
pathologists regularly see the morphological evidence of this cell death in the form of
tumour cell necrosis and apoptotic cells. Additional evidence comes from the apparent
mismatch between the mitotic rate and the doubling time of cancers. Doubling time
has been measured for a number of different cancers but for illustration I will use the
doubling time of lung cancers. Arai et al. [34] measured the mean doubling time of a
series of 237 lung cancers as 166.3 days. Table 3 shows the mean number of genera-
tions for different tumours with various doubling times. A tumour with a doubling
Table 2 Effect of differing relative rates of increase on clonal evolution
rA -r a Number of generations needed for the relative
proportion of a clone to change from 1% to 99%
0.01 919
0.05 184
0.10 92
0.50 18
0.75 12
1.00 9
2.00 5
5.00 2
Number of cell generations required in a two clone model for a clone to go from a relative proportion of 1% to a
relative proportion of 99% given a range of differences in the intrinsic rate of increase of the two clones. rA -r a =t h e
intrinsic rate of increase of clone A minus the intrinsic rate of increase of clone a. See text for further explanation.
Table 3 Estimated number of generations over a 20 year period for tumours with
different doubling times
Doubling time (days) Generations/20 yrs
25 292
50 146
75 97
100 73
125 58
166 44
150 49
200 37
300 24
400 18
500 15
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lifespan of the tumour) and no cell death would have experienced an average of 44 cell
generations (this is in the same range as the 40 population doublings needed to pro-
duce a tumour of maximal size compatible with life [35]. However, if we look at the
observed mitotic rates of cancers we would predict a much faster growth rate. For
example, in a cancer with a mitotic rate of one mitosis per 1000 cells and assuming a
time of mitosis similar to that reported for human epidermis (90 minutes [36]), we
would expect a tumour doubling time of 44 days if all cells were dividing at the same
rate (Table 3). A mitotic count of one mitosis per 100 tumour cells would give an esti-
mated doubling time of less than 5 days. One mitotic figure count of one per 1000
cells is not an especially high rate considering that one to two mitotic cells per micro-
scopic high power field are commonly encountered in carcinomas and correspond to
approximately one mitosis per 300 cells (personal observation). This apparent discre-
pancy between the observed doubling times and the expected doubling times given a
realistic range of observed mitotic rates is easily explained if the vast majority of
tumour cells die. This would also allow a much higher number of generations to exist
within a cancer than would be predicted solely on the basis of the observed doubling
times. For example, in the case of a cancer with 1 in 1000 observed cells in mitosis,
166 generations (not 44) could exist in 20 years if all cells divided at an equal rate. If
the tumour contains cancer stem cells, these might be expected to divide at the much
faster rate of 50 - 100 generations per year [4], giving 1000-2000 cell generations over
the hypothetical 20 year life-span of a tumour. The much larger number of generations
present in cancer stem cells would also increase the potential number of mutations
which could accumulate in these cells.
Although the strength of natural selection among tumour cell clones has not been
quantified, we can explore the consequences for clonal evolution based on hypothetical
levels of selection pressure. Selection can be defined in a number of different ways but
for this discussion, I will be referring to selection as the relative advantage of one
clone over another. Thus if a given clone is said to have a selective advantage of 0.01,
this means that, on average, members of that clone will pass on 1% more offspring to
the next generation as compared to a second clone. The change in clonal frequency
(expressed as the change in proportion of clone A to clone a is described by the equa-
tion G = [ln(PA
(t)/Pa
(t))-l n ( P A
(0)/Pa
(0))]/ln (1+s) [22] where G = the number of gen-
erations, PA
(0) = the initial proportion of clone A, Pa
(0) = the initial proportion of
clone a, PA
(t) = the final proportion of clone A, Pa
(t) = the final proportion of clone a,
and s = the selective advantage of clone A over clone a. Analogous to Table 2, Table 4
shows the effect of various selection coefficients on the rate at which one clone can
replace another (defined as a change in frequency from 1% to 99%). Table 4 shows
that in order for clonal replacement to occur at a rate of one new clone per 30 cell
generations (to allow the incorporation of 5 functionally important mutations in 150
cell generations) we would require an s of slightly less than 0.5. In contrast, for cancer
stem cells with 1000 generations, the equivalent number is considerably less, in the
range of 0.05 (Table 4). Although a direct comparison would obviously not be valid, it
is interesting to note that these levels of selection (0.05 - 0.50) are within the range of
selection coefficients observed among species of free-living organisms, where
the related measurement of linear selection gradient averages about 0.16 [37].
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than that observed among free-living organisms. Strictly speaking, the equation shown
above is applicable only to populations with discrete generations and the more proper
comparison of different levels of selection in a population with overlapping generations
would be to compare the differences in the intrinsic rates of increase as explained ear-
lier [22]. However, from a practical point of view the two approaches produce similar
results and that the equation utilizing the selection coefficient is more instructive in
this setting.
The special case of frequency dependent selection
A final concept from theoretical population genetics which may have some relevance
in explaining the behaviour of certain cancers is the concept of frequency-dependent
selection [1]. Frequency dependent selection describes the situation where two different
species (in our case clones) exist and the fitness of each is greater when it is rare [20].
In the context of tumour biology this could refer to the situation where a cancer con-
tains two different populations - either different clones of the same cell type or entirely
different cell types in the case of biphasic neoplasms. Mathematically, this can be
described by the equations dx/dt = r1x (1-bx-cy) and dy/dt = r2y (1-fx-gy) [20] where
x and y are the different cell types, b and g describe the degree of self-inhibition, c and
f describe the degree of inhibition of the other cell type, r is the intrinsic rate of
increase of each cell type and t is the time interval. Depending on the relative values
of b,g,c and f, it can be shown that the relative density of two types will tend to fluctu-
ate around a stable equilibrium [20], thus maintaining a cancer containing two (or
more) distinct cell types. This provides a possible explanation for the existence of
biphasic tumours such as synovial sarcomas, the relationship between tumour cells and
their surrounding stroma, as well as the existence of the stable long term genetic het-
erogeneity which has been observed in some cancers [38,39].
Discussion
In this paper I have attempted to explore some aspects of theoretical population genet-
ics of asexual species and show how these might apply to the population dynamics of
cancer cell clones. A few general trends emerge from this exercise. First of all, it is pre-
dicted that clonal evolution will be faster (i.e. require fewer generations) when popula-
tion sizes are smaller. Thus evolution may proceed faster in smaller cancers, in cancers
with greater genetic heterogeneity or in cancers in which stem cells are the drivers of
Table 4 Effect of differing selective advantages on the rate of clonal evolution
Selective advantage of
clone A over clone a
Number of generations needed for the relative
proportion of clone A to change from 1% to 99%
0.01 924
0.05 188
0.10 96
0.50 23
0.75 16
1.00 13
2.00 8
5.00 5
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cally address the absolute or relative frequency of cancer stem cells, the only require-
ment is that they remain less numerous than the non-stem cells. The models
presented here also do not address the presence or absence of genetic instability. It is
anticipated that genetic instability would increase the mutation rate of all cells and so
the predicted relative rates of evolutionary change would remain valid.
The number of generations necessary for mutations to numerically increase in the
tumour will depend on either differences in the intrinsic rate of increase of different
cancer cell clones or differences in the relative fitness of the clones as measured by
relative differences in the selection on each clone. In reality it is likely that a combina-
tion of these factors is at work, simultaneously or sequentially, within a tumour. I have
given illustrations of the estimated average number of generations for mutations to
accumulate within a cancer cell clone given different relative rates of increase and dif-
ferent relative strengths of selection. The major conclusion from these comparisons is
that if all somatic cells in a cancer participate in clonal evolution, the number of gen-
erations needed to accumulate the necessary number of mutations is within a plausible
range, particularly if the number of cell generations within a cancer is greater than pre-
viously suspected due to a high cancer cell death rate. If clonal evolution is driven by
the accumulation in mutations in cancer stem cells, the differences in intrinsic rates of
increase and/or differences in selection need be approximately an order of magnitude
less to result in the same rate of clonal evolution.
Whether cancer clones replace each other because of different intrinsic rates of
increase or because of differences in the level of selection may be of interest. A possi-
ble method to distinguish between these mechanisms is suggested by the prediction
that the potentially high level of selection among cancer cell clones would be expected
to leave evidence of selection at the genetic level in the form of different rates of
synonymous and non-synonymous base substitutions among different clones in the
same tumour. The existence of such a difference in substitution rates would provide
strong evidence of selection pressure versus a difference in intrinsic rates of increase.
This technique may offer a novel and powerful method for detecting positive selection
in cancer cell clones. The caveat of course is that one could only comment on the
strength of selection acting on the nucleotide sequence in question. Comparison of the
relative strength of positive selection in early and late cancers could also provide a way
of mapping the relative selection pressures of clones as they evolve. Most importantly,
isolation/microdissection of individual stem cells with subsequent genome amplifica-
tion and sequencing followed by comparison of the relative strength of selection with
n o n - s t e mc e l l sc o u l df u r t h e r m o r ep r o v i d eam e t h o do ft e s t i n gt h er e l a t i v es t r e n g t ho f
selection of stem cells and non-stem cells and thereby indirectly testing the entire
stem cell paradigm. Finally, it might be assumed that selection pressure acting on can-
cer cells would be in the form of purifying selection to preserve gene function in the
face of the anticipated large number of mutations within a cancer. However, the com-
parison of the relative rates of synonymous and non-synonymous base substitutions
would also allow the detection of diversifying selection (if there was selection to alter
the structure of proteins of clones occupying different ‘ecological niches’ within the
cancer).
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the prediction that chemotherapy and surgical debulking of cancers may result in
more rapid clonal evolution of the remaining tumour cells.
A major technical hurtle in the further study of clonal dynamics within a cancer has
been the lack of an efficient method to estimate intra-tumour clonal diversity, and
especially techniques that can be applied to archived clinical samples. A recent advance
in this area has been the description of a method to quantify clonal diversity using a
combination of FISH and immunofluorescence staining [30]. The application of this or
other methods to quantify intra-tumour clonal diversity will lead to an exciting new
era in the study of the dynamics of tumour clonal dynamics, and will aid in the testing
of the predictions stemming from population genetics.
Conclusions
Cancer cell clonal evolution has been the subject of intense recent interest; the applica-
tion of asexual theoretical population genetics to cancer biology has the potential to
lead to new insights into this process. The inclusion of cancer stem cells into models
of clonal evolution leads to the prediction that in cancers which contain stem cells,
clonal evolution of stem cells may be considerably faster than somatic cell evolution.
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